BWCS
FOLD

Beirne Wealth Consulting Services’s Amicus Therapeutics FOLD Stock Holding History

Beirne Wealth Consulting Services’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,933
Closed -$155K – 118
2023
Q4 		$155K Buy
+10,933
New +$124K 0.08% 147

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Beirne Wealth Consulting Services's FOLD Position: Q1 2024 in Review

Beirne Wealth Consulting Services sold out of Amicus Therapeutics (FOLD) in Q1 2024, closing a stake of 10,933 shares — an estimated $155K sold.

Beirne Wealth Consulting Services first reported a position in FOLD in Q4 2023 and held it in 1 quarter. The position peaked at $155K in Q4 2023. 254 funds tracked by Wall St. Rank hold FOLD as of Q1 2024.

  • Beirne Wealth Consulting Services reported no remaining Amicus Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Beirne Wealth Consulting Services sold 10,933 Amicus Therapeutics shares in Q1 2024, an estimated $155K.
  • Beirne Wealth Consulting Services first reported a position in Amicus Therapeutics in Q4 2023 and held it in 1 quarter.
  • Beirne Wealth Consulting Services's Amicus Therapeutics position peaked at $155K in Q4 2023.
  • 254 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2024.

Based on Beirne Wealth Consulting Services's 13F filing for Q1 2024, filed 13 May 2024.